The impact of socio-environmental factors on doxycycline post-exposure prophylaxis awareness in the US: a cross-sectional study
Krishen D. Samuel A B , Matthew S. Ellis C and Mance E. Buttram
A B *
A
B
C
Abstract
We investigated awareness and use of doxycycline post-exposure prophylaxis (doxyPEP) in the US. DoxyPEP has preventative benefits for bacterial STIs among people assigned male at birth. We considered how individual, interpersonal and social determinants of health, such as state-level LGBTQ equality, impact doxyPEP awareness.
We conducted an online snapshot cross-sectional survey in June 2023. Survey questions included demographics, sexual and substance use behaviours, and socio-environmental factors, and provided a short explanation of doxyPEP, with questions regarding prior awareness and use.
Among a racially diverse sample of 196 participants (median age 33 years), 94% identified as cisgender men, 26% were aware of doxyPEP, whereas only 14 (7%) had ever used it. Factors significantly associated with awareness included being college educated (OR 2.50, 95% CI 1.09–5.74), a past year bacterial STI (OR 4.20, 95% CI 1.97–8.89), having discussed HIV pre-exposure prophylaxis with a health care provider (OR 3.88, 95% CI 1.99–7.57) and having taken HIV pre-exposure prophylaxis (OR 2.29, 95% CI 1.11–4.70). Socio-environmental factors associated with doxyPEP awareness included living in a large urban city (OR 2.14, 95% CI 1.12–4.10) and living in a state with higher levels of LGBTQ policy equality (OR 2.18, 95% CI 1.07–4.44).
Considering the disproportionate impact of bacterial STIs on men who have sex with men, especially those living in lower LGBTQ equality regions, such as the Southern US, our study emphasises how socio-environmental factors may limit awareness and uptake of novel biomedical approaches that have the potential to prevent morbidity and enhance sexual health.
Keywords: chlamydia, doxycycline, doxyPEP, gonorrhoea, LGBTQ health, men who have sex with men, sexually transmitted diseases, sexually transmitted infections, STDs, STIs, syphilis.
References
1 US Centers for Disease Prevention and Control. Sexually Transmitted Disease Surveillance, 2021; 2023. Available at https://www.cdc.gov/std/statistics/2022/2021-STD-Surveillance-Report-PDF_ARCHIVED-2-16-24.pdf
2 Molina JM, Charreau I, Chidiac C, Pialoux G, Cua E, Delaugerre C, Capitant C, Rojas-Castro D, Fonsart J, Bercot B, Bébéar C, Cotte L, Robineau O, Raffi F, Charbonneau P, Aslan A, Chas J, Niedbalski L, Spire B, Sagaon-Teyssier L, Carette D, Mestre SL, Doré V, Meyer L, ANRS IPERGAY Study Group. Post-exposure prophylaxis with doxycycline to prevent sexually transmitted infections in men who have sex with men: an open-label randomised substudy of the ANRS IPERGAY trial. Lancet Infect Dis 2018; 18(3): 308-17 PMID:.
| Crossref | Google Scholar | PubMed |
3 Luetkemeyer AF, Donnell D, Dombrowski JC, Cohen S, Grabow C, Brown CE, Malinski C, Perkins R, Nasser M, Lopez C, Vittinghoff E, Buchbinder SP, Scott H, Charlebois ED, Havlir DV, Soge OO, Celum C, DoxyPEP Study Team. Postexposure doxycycline to prevent bacterial sexually transmitted infections. N Engl J Med 2023; 388(14): 1296-306 PMID:.
| Crossref | Google Scholar | PubMed |
4 La Ruche G, Goubard A, Bercot B, Cambau E, Semaille C, Sednaoui P. Gonococcal infections and emergence of gonococcal decreased susceptibility to cephalosporins in France, 2001 to 2012. Euro Surveill 2014; 19(34): 20885.
| Crossref | Google Scholar |
5 Wilson DP, Prestage GP, Gray RT, Hoare A, McCann P, Down I, Guy RJ, Drummond F, Klausner JD, Donovan B, Kaldor JM. Chemoprophylaxis is likely to be acceptable and could mitigate syphilis epidemics among populations of gay men. Sex Transm Dis 2011; 38(7): 573-9.
| Crossref | Google Scholar |
6 Park JJ, Stafylis C, Pearce DD, Taylor J, Little SJ, Kojima N, Gorin AM, Klausner JD. Interest, concerns, and attitudes among men who have sex with men and health care providers toward prophylactic use of doxycycline against Chlamydia trachomatis infections and syphilis. Sex Transm Dis 2021; 48(9): 615-9.
| Crossref | Google Scholar |
7 Spinelli MA, Scott HM, Vittinghoff E, Liu AY, Coleman K, Buchbinder SP. Note: High interest in doxycycline for sexually transmitted infection post-exposure prophylaxis (doxycycline-PEP) in a multi-city survey of men who have sex with men (MSM) using a social-networking app. Sex Transm Dis 2019; 46(4): e32-e34 PMID:.
| Crossref | Google Scholar | PubMed |
8 Oldenburg CE, Perez-Brumer AG, Hatzenbuehler ML, Krakower D, Novak DS, Mimiaga MJ, Mayer KH. State-level structural sexual stigma and HIV prevention in a national online sample of HIV-uninfected men who have sex with men in the United States. AIDS 2015; 29(7): 837-845 PMID:.
| Crossref | Google Scholar | PubMed |
9 Martos AJ, Wilson PA, Meyer IH. Lesbian, gay, bisexual, and transgender (LGBT) health services in the United States: Origins, evolution, and contemporary landscape. PLoS ONE 2017; 12(7): e0180544 PMID:.
| Crossref | Google Scholar | PubMed |
11 The Movement Advancement Project. LGBTQ Equality by State. Movement Advancement Project; 2023. Available at https://www.lgbtmap.org/equality-maps
12 O’Halloran C, Croxford S, Mohammed H, Gill ON, Hughes G, Fifer H, Allen H, Owen G, Nutland W, Delpech V, Saunders JM. Factors associated with reporting antibiotic use as STI prophylaxis among HIV PrEP users: findings from a cross-sectional online community survey, May–July 2019, UK. Sex Transm Infect 2021; 97(6): 429-33.
| Crossref | Google Scholar |
13 Nguyen VK, Greenwald ZR, Trottier H, Cadieux M, Goyette A, Beauchemin M, Charest L, Longpré D, Lavoie S, Tossa HG, Thomas R. Incidence of sexually transmitted infections before and after preexposure prophylaxis for HIV. AIDS 2018; 32(4): 523-30.
| Crossref | Google Scholar |
14 US Centers for Disease Control and Prevention. Guidelines for the Use of Doxycycline Post-Exposure Prophylaxis for Bacterial Sexually Transmitted Infection (STI) Prevention; Request for Comment and Informational Presentation; 2023. Available at https://www.federalregister.gov/documents/2023/10/02/2023-21725/guidelines-for-the-use-of-doxycycline-post-exposure-prophylaxis-for-bacterial-sexually-transmitted
15 California Department of Public Health. Doxycycline Post-Exposure Prophylaxis (doxy-PEP) for the Prevention of Bacterial Sexually Transmitted Infections (STIs); 2023. Available at https://www.cdph.ca.gov/Programs/CID/DCDC/CDPH%20Document%20Library/CDPH-Doxy-PEP-Recommendations-for-prevention-of-STIs.pdf
16 The Department of Health and Human Services, USA. Sexually Transmitted Infections National Strategic Plan for the United States, 2021–2025; 2022. Available at https://www.hhs.gov/sites/default/files/STI-National-Strategic-Plan-2021-2025.pdf
17 Hojilla JC, Hurley LB, Marcus JL, Silverberg MJ, Skarbinski J, Satre DD, Volk JE. Characterization of HIV preexposure prophylaxis use behaviors and HIV incidence among US adults in an integrated health care system. JAMA Netw. Open 2021; 4(8): e2122692 PMID:.
| Crossref | Google Scholar | PubMed |
18 San Francisco AIDS Foundation. SFAF leads in new “Doxy PEP” prevention strategy; 2023. Available at https://www.sfaf.org/collections/breaking-news/sfaf-leads-in-new-doxy-pep-prevention-strategy/
